Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

October 15, 2008 (Vol. 28, No. 18)

Fine-Tuning the Design of GPCR Therapeutics

Understanding Allosteric Modulation and Functional Selectivity Are Key Priorities

  • Bryan Roth, M.D., Ph.D., director of the National Institute of Mental Health’s psychoactive drug screening program at the University of North Carolina, suggests that the information printed in textbooks of pharmacology is “far from reality.” He is referring to recent discoveries about the incredible complexity of GPCR, the theme ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.